BioCentury
ARTICLE | Clinical News

ACH-3422: Interim Phase I data

January 5, 2015 8:00 AM UTC

Interim data from treatment-naïve patients with HCV genotype 1 infection in a double-blind, placebo-controlled Phase I trial showed that once-daily 700 mg oral ACH-3422 led to a mean maximal reduction...